新冠再现感染潮，亚洲疫情概念股大涨

Group 1 - The resurgence of COVID-19 in Asia has led to increased expectations for demand in testing and vaccine production, resulting in a collective surge in stock prices of related companies [1][3] - South Korean diagnostic kit manufacturer Sugentech saw its stock price rise by as much as 29%, while Japanese vaccine manufacturer Daiichi Sankyo's stock increased by 7.4% due to an upgraded target price from UBS [1] - Other companies, such as Shanghai Junshi Bioscience in Hong Kong, also experienced stock price increases, with a rise of 4.3% [1] Group 2 - The new wave of COVID-19 is spreading rapidly in Asia, with predictions that it may reach levels seen during last summer's peak, according to the Chinese Center for Disease Control and Prevention [3] - The Korea Disease Control and Prevention Agency (KDCA) has extended the seasonal COVID-19 vaccination period by two months until the end of June, particularly recommending early vaccination for vulnerable groups [3] - The stock prices of various South Korean COVID-19 testing and vaccine companies, including Humasis, LabGenomics, Seegene, and SD Biosensor, have generally increased, with SK Bioscience's stock rising by 7.2% [3]